A seasoned Drug Discovery Professional and a Pharmaceutical Consultant with over two decades of experience, developing therapeutics for multiple human disorders. Presently focusing on decoding the mechanisms that drive chronic inflammation across numerous immune-mediated inflammatory disorders or IMIDs. An expert in leveraging artificial intelligence-augmented scientific analyses and drug re-innovation to identify novel disease-drug combinations across major therapeutic areas, including rare diseases. - Previous Lead researcher for Translational and nonclinical research at BioXcel Therapeutics, and instrumental in the discovery of BXCL501 (IGALMI™), a sublingual film designed to support a cooperative approach to agitation intervention, that was successfully launched in 2022. - Instrumental in identifying various novel disease-drug combinations in CNS, hematology, and other common and rare diseases.- A visionary researcher and translational expert with extensive experience in conducting multi-year projects on autoimmune, respiratory, and metabolic diseases. -Have led numerous Novel Research programs and collaborations in the past, provided scientific insights to multi-disciplinary drug discovery teams and validated novel concepts using cell line, animal, and human proof of concept studies.- Provided high-level strategic insights and recommendations to the biopharma industry for developing novel drugs and prioritizing target-indication programs across multiple therapeutic areas. A stellar track record in the scientific community with in-depth knowledge of newer technologies and advances in pharmacology, a strong patent record (4 US patents granted and 3 pending), and numerous publications (17) in peer-reviewed scientific journals. A highly awarded scientist with outstanding achievements in the field. Specialties: Artificial Intelligence, Design and Execution of Proof of Concept Studies, Translational Drug Discovery, Strategic Pharma Consulting, Orphan Diseases, and Drug Re-innovation.